Roche: Divarasib Shows Superiority Over Approved KRAS G12C Inhibitors In Phase III NSCLC Trial

Achieves Statistically Significant Improvements In Progression-Free Survival And Overall Survival Data To Be Submitted To Health Authorities And Presented At Upcoming Medical Meeting